

**Table 3. Associations of NAFLD and MAFLD with CKD (defined as either CKD stage  $\geq 1$  or CKD stage  $\geq 3$ ) and abnormal albuminuria (defined as ACR  $\geq 3$  mg/mmol) as well as associations of MAFLD severity (stratified by NFS scores) with CKD and abnormal albuminuria.**

<i>CKD stage <math>\geq 1</math></i>	<b>Prevalence of CKD stage <math>\geq 1</math> (n, %)</b>	<b>Model 1 (OR and 95% CI)</b>	<i>P</i>	<b>Model 2</b>	<i>P</i>	<b>Model 3</b>	<i>P</i>
<b>No NAFLD</b>	1644/8019 (20.50%)	Reference		Reference		Reference	
<b>NAFLD</b>	1209/4552 (26.56%)	1.40 (1.29-1.53)*	<0.001	1.14 (1.03-1.25)*	0.011	1.06 (0.96-1.17)	0.243
<b>No MAFLD</b>	1730/8777 (19.71%)	Reference		Reference		Reference	
<b>MAFLD</b>	1123/3794 (29.60%)	1.71 (1.56-1.87)*	<0.001	1.22 (1.10-1.35)*	<0.001	1.12 (1.01-1.24)*	0.033
<i>MAFLD Severity</i>							
<b>No MAFLD</b>	1730/8777 (19.71%)	Reference		Reference		Reference	
<b>MAFLD with NFS &lt; -1.455</b>	317/1880 (16.86%)	0.83 (0.72-0.94)*	0.004	1.05 (0.91-1.22)	0.499	1.01 (0.88-1.17)	0.850
<b>MAFLD with <math>-1.455 \leq \text{NFS} &lt; 0.676</math></b>	593/1540 (38.50%)	2.55 (2.27-2.86)*	0.001	1.29 (1.13-1.47)*	0.001	1.16 (1.02-1.32)*	0.030
<b>MAFLD with NFS <math>\geq 0.676</math></b>	213/374 (56.95%)	5.38 (4.36-6.66)*	0.001	1.58 (1.26-1.99)*	0.001	1.34 (1.06-1.69)*	0.015
<i>CKD stage <math>\geq 3</math></i>							
	<b>Prevalence of CKD stage <math>\geq 3</math> (n, %)</b>	<b>Model 1</b>	<i>P</i>	<b>Model 2</b>	<i>P</i>	<b>Model 3</b>	<i>P</i>
<b>No NAFLD</b>	1189/8019 (14.83%)	Reference		Reference		Reference	
<b>NAFLD</b>	812/4552 (17.83%)	1.25 (1.13-1.38)*	<0.001	0.96 (0.86-1.08)	0.534	0.94 (0.83-1.05)	0.271
<b>No MAFLD</b>	1232/8777 (14.04%)	Reference		Reference		Reference	

<b>MAFLD</b>	769/3794 (20.27%)	1.56 (1.41-1.72)*	<0.001	1.04 (0.92-1.17)	0.545	1.00 (0.89-1.13)	0.970
<i>MAFLD Severity</i>							
<b>No MAFLD</b>	1232/8777 (14.04%)	Reference		Reference		Reference	
<b>MAFLD with NFS &lt; -1.455</b>	158/1880 (8.40%)	0.56 (0.47-0.67)*	0.001	0.73 (0.60-0.88)*	0.001	0.82 (0.67-0.99)*	0.042
<b>MAFLD with -1.455 ≤ NFS &lt; 0.676</b>	437/1540 (28.38%)	2.43 (2.14-2.75)*	0.001	1.11 (0.96-1.28)	0.158	1.01 (0.92-1.24)	0.369
<b>MAFLD with NFS ≥ 0.676</b>	174/374 (46.52%)	5.33 (4.31-6.59)*	0.001	1.49 (1.18-1.88)*	0.001	1.18 (0.93-1.51)	0.176
<i>ACR ≥ mg/mmol</i>	<b>Prevalence of ACR ≥3 mg/mmol (n, %)</b>	<b>Model 1</b>	<b>P</b>	<b>Model 2</b>	<b>P</b>	<b>Model 3</b>	<b>P</b>
<b>No NAFLD</b>	679/8019 (8.47%)	Reference		Reference		Reference	
<b>NAFLD</b>	581/4552 (12.76%)	1.58 (1.41-1.78)*	<0.001	1.35 (1.19-1.52)*	<0.001	1.18 (1.04-1.33)	0.011
<b>No MAFLD</b>	728/8777 (8.29%)	Reference		Reference		Reference	
<b>MAFLD</b>	532/3794 (14.02%)	1.80 (1.60-2.03)*	<0.001	1.44 (1.27-1.63)*	<0.001	1.20 (1.06-1.37)*	0.005
<i>MAFLD Severity</i>							
<b>No MAFLD</b>	728/8777 (8.29%)	Reference		Reference		Reference	
<b>MAFLD with NFS &lt; -1.455</b>	183/1880 (9.73%)	1.19 (1.01-1.41)*	0.015	1.24 (1.04-1.48)*	0.015	1.16 (0.97-1.38)	0.106
<b>MAFLD with -1.455 ≤ NFS &lt; 0.676</b>	259/1540 (16.81%)	2.24 (1.92-2.61)*	<0.001	1.52 (1.30-1.79)*	<0.001	1.21 (1.02-1.44)*	0.026
<b>MAFLD with NFS ≥ 0.676</b>	90/374 (24.06%)	3.50 (2.73-4.49)*	<0.001	1.89 (1.45-2.45)*	<0.001	1.32 (1.00-1.74)*	0.049

Model 1 is univariable logistic regression analysis (unadjusted model).

Model 2 includes sex, age, ethnicity and alcohol intake as covariates.

Model 3 includes sex, age, ethnicity, alcohol intake and pre-existing diabetes as covariates.

Data are expressed as odds ratios (OR) and 95% confidence intervals (95% CI). \* $P < 0.05$  or less